This article is more than 5 years old. Information may no longer be current.

Othera, NEI collaborate in dry AMD study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EXTON, Pa. — A topical eye drop developed to slow enlargement of the atrophic area in the macula and prevent dry age-related macular degeneration from becoming wet AMD has entered phase 2 trials, the drug’s developer said in a press release.

Othera Pharmaceuticals Inc., in conjunction with the National Eye Institute, has begun a phase 2 trial of OT-551 in 10 patients with geographic atrophy. Once patient enrollment is complete, participants will receive three daily doses of the drop over 2 years, according to a press release. Primary efficacy measures will include the percent change in area of geographic atrophy in each eye, as measured by fundus photography.

OT-551 is a low molecular weight compound that has “shown benefit in various animal models of macular degeneration, exhibiting both anti-inflammatory and anti-angiogenic effects,” according to the release. The compound is also in phase 2 trials for the prevention or slowing the progression of post-vitrectomy nuclear cataract. Additional phase 2 studies are being planned, the company said.